http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4963677-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_af737d167c026fd865fb68df681ea49a |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D513-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D513-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D513-16 |
| filingDate | 1988-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1990-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e405e517674c234b41d79d74d0fd8990 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c73986545941696cf27d7d6f3582bcb7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_559da1765a73c440a363e1a074ee2b22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0621fce5603fd09ec99437d063e9a8f4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba3738402c607fdf5216d9e03c31e157 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe5cc4a0dc16faad9b8adc1a60c83156 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4e57b9ae4e430745d00e576b63c422db http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5affa8cba93b54dc459ecc0410db363b |
| publicationDate | 1990-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-4963677-A |
| titleOfInvention | Heterocyclic lactam compounds |
| abstract | A compound of the formula <IMAGE> I or <IMAGE> II and pharmaceutically acceptable salts thereof, in which A is -N=N-NH-, -X-C(R2)=N-, -N=C(R2)-X-, -X-C(R2)-CH(R2)=N- or -N=C(R2)-CH(R2)-X-, wherein X is sulphur, oxygen or nitrogen and R2 is provided that where two R2-groups are present in the A group one of the R2 groups is hydrogen, amino, substituted amino, C1-6alkyl, substituted acylamino or one of the following groups: <IMAGE> <IMAGE> <IMAGE> <IMAGE> <IMAGE> <IMAGE> <IMAGE> +TR <IMAGE> wherein Ra is hydrogen, amino, substituted amino, C1-6alkoxy, heterocyclic five membered ring or -NHCOR', wherein R' is C1-6alkyl, aryl or heterocyclic five membered ring, Rb is hydrogen, C1-6alkoxy, C1-6alkylthio or hydroxy, Rc is hydrogen, C1-6alkyl or oxygen and Rd is C1-6alkyl or oxygen, Re is hydrogen, hydroxy or C1-6alkoxy, Rf is C1-6alkyl, provided that where two R2-groups are present in the A group, one of the R2 groups is hydrogen; B is -(CH2)m-C(R3R4)-(CH2)n-, -C(R3)=CH-, -CH=C(R3)-, -O-[C(R3R4)]n-, -[C(R3R4)]n-O-, -S-[C(R3R4)]n- or -[C(R3R4)]n-S- wherein R3 and R4, which can be independently the same or different, are hydrogen, C1-6alkyl, aryl (preferably phenyl) or pyridyl and m and n are independently zero or 1; D is either oxygen or sulphur; the two R-groups are indepenently hydrogen, C1-6alkoxy, C1-6alkyl, amino, acylamino or substituted acylamino, nitro, halogen, cyano, aldehyde, carboxy, carbamoyl; R1 is a hydrogen or C1-6alkyl or R and R1 form together a fused 6-membered heterocyclic ring. The compound is effective in the treatment of congestive heart failure. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5750542-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008234237-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6326382-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8173813-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6498255-B2 |
| priorityDate | 1987-12-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 258.